Catálogo de publicaciones - libros

Palabras clave – provistas por la editorial

hereditary hemorrhagic telangiectasia; rare diseases; telangiectasis; transforming growth factor-beta (TGF-β); Smad pathway; gastrointestinal bleeding; epistaxis; nosebleeds; tacrolimus; nasal ointment; genetic disease; rare disease; hereditary hemorrhagic telangiectasia (HHT); telangiectases; mechanical damage; sun-induced trauma; vascular malformations; Endoglin; activin-receptor-like kinase 1; Hereditary Hemorrhagic Telangiectasia; antithrombotic therapy; anticoagulants; antiplatelets; bleeding; safety; HHT; ALK1; endoglin; raloxifene; bazedoxifene; tranexamic acid; propranolol; FK506; etamsylate; N-acetylcysteine; pulmonary arteriovenous malformations; transcatheter embolotherapy; screening; guidelines; Hereditary hemorrhagic telangiectasia; pediatrics; genotype–phenotype correlation; arteriovenous malformation; ENG; ACVRL1; SMAD4; microRNA; biomarker; plasma; arteriovenous malformations (AVMs); angiogenesis; activin receptor-like kinase 1 (ALK1); transforming growth factor beta (TGF-β); bone morphogenetic protein (BMP); propranolol gel; epistaxis severity score; nasal endoscopy; antiangiogenic properties; non-coding RNAs; microRNAs; long non-coding RNAs; biomarkers; endothelial cells; hereditary hemorrhagic telangiectasia (HHT), second-hit; arteriovenous malformation (AVM); Smad4; inflammation; shear stress; vascular injury; somatic mutation; cell adhesion; vascular endothelial growth factor (VEGF); telangiectasia; hereditary hemorrhagic; survival; life expectancy; pulmonary arteriovenous malformation; contrast enhanced magnetic resonance angiography; liver; MRI; ultrasound; AVM; bevacizumab; Osler–Weber–Rendu; hereditary hemorrhagic telangiectasia/HHT/osler’s disease; cerebral ischemic lesions; catheter based embolization therapy